Developed by            





Call for Applicants

Australian scientists are recognized for world class innovation, but historically the challenge has been translating that work into commercial success. The work of Australian of the Year, Professor Ian Frazer, is a success that should be repeated.

“Australian science is rich in ideas and innovation, but the best medical discoveries will not help one person unless we understand the commercialisation process and can navigate the journey from compound to life-changing or life-saving medicine.”

Professor Ian Frazer, 2006 Australian of the Year


Now, Merck Sharp & Dohme* and Advance† have formed a partnership to open new doors for Australian scientists with the Advancing BioBusiness Award. The Award will provide the next generation of leaders in Australian biotechnology with access to leading institutions, companies and individuals in the US involved in commercialising life sciences. The Award will facilitate greater opportunities for connection and exposure to the global market and commercialisation processes for Australian discoveries. Through the Award, two Australian scientists will have the support to build valuable international networks and collaborations that will benefit their business and the Australian life sciences industry.


The two recipients of the Advancing BioBusiness Award will attend the BIO International Convention in Boston, May 2007, as well as participate in a tailored program of meetings with leading organisations involved in the life sciences sector.

The Award will provide business class air travel and accommodation for the recipients to attend BIO in the US, and recipients will also undertake an intensive program for them to interact with leading scientists, managers, business leaders and finance providers involved in global commercialisation of life science research. Each program will be specifically tailored, in consultation with the recipient, to reflect their particular research focus and commercial needs, in areas including research planning, IP management, manufacturing planning, regulatory affairs management and market forecasting.

The Award recipients will be required to share their experience of the program on return to Australia. This may include the preparation of a report as well as presentations at an appropriate forum and/or scientific meeting.

Applications are invited from Australian-based scientists who have completed their post doctoral training and are conducting research in an institution or biotech company in Australia.

The applications will be assessed by a panel of experts including Dr Graeme Blackman, Chairman and Managing Director, Institute of Drug Technology Australia Ltd, Dr Anna Lavelle, Chief Executive Officer, AusBiotech Ltd and Professor Graham Macdonald, External Licensing Coordinator, Merck Sharp & Dohme, Australia.


Please click on the following link to download an application form (in pdf format), which also contains full terms and conditions of the Advancing BioBusiness Award:

 Download the application form

The closing date for applications is 25th January 2007.


*Merck Sharp & Dohme (Australia) Pty Limited is the Australian subsidiary of the global research-based pharmaceutical company Merck & Co., Inc., Whitehouse Station, N.J., U.S.A. Merck Sharp & Dohme (Australia) Pty Limited 54-68 Ferndell Street South Granville NSW 2142.

†Advance builds links between the one million Australians in our diaspora making their mark in boardrooms, science laboratories, institutions and communities worldwide (http//